Full steam ahead., page-6

It has been defended Mooosie because it now belongs solely with Noxopharm. NOX management has cleared up the issue in a timely manner - particularly if more abscopal outcomes are achieved from ongoing clinical trials during 2018.

From that viewpoint, the only company that may stand to rue an early settlement would be Novogen/Kazia. It stands to reason that the Noxopharm board would have a vastly better forward looking capability with regard to how the DARRT trials for instance are going to pan out. There is a logic from a Noxopharm standpoint to achieve a quick resolution. In what could have been a costly and protracted stalemate, there is no doubt that the Novogen/Kazia board blinked first. Using your words, they are the ones who did not defend this issue to the fullest extent.

In the immediate future, given their shaky position perhaps Novogen/Kazia have done very well. But in the longer view, I wouldn't be so certain.

Consider this. If GDC -0084 is successful, then Novogen/Kazia will be tapping into an income stream that should make its holding in Noxopharm seem almost irrelevant. But what if GDC fails?

Seriously, if GDC - 0084 is a flop - and history says in all likelihood that it will be - then what real benefit will the company's stake in Noxopharm be to its shareholders?

By the way, have you thought to ask Kilinwata its motive for ditching its Novogen/Kazia shares?